{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T19:57:52Z","timestamp":1792612672055,"version":"4.5.0"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2016,4,29]],"date-time":"2016-04-29T00:00:00Z","timestamp":1461888000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["FP7-242209-BIOSTAT-CHF; EudraCT 2010\u2013020808\u201329"],"award-info":[{"award-number":["FP7-242209-BIOSTAT-CHF; EudraCT 2010\u2013020808\u201329"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Despite major improvements in pharmacological and device treatments, heart failure remains a syndrome with high morbidity and mortality, poor quality of life, and high health-care costs. Given the extensive heterogeneity among patients with heart failure, substantial differences in the response to therapy can be expected. We hypothesize that individualized therapy is an essential next step to improve outcomes in patients with heart failure.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The BIOlogy Study to TAilored Treatment in Chronic Heart Failure (BIOSTAT-CHF) included 2516 patients with worsening signs and\/or symptoms of heart failure from 11 European countries, who were considered to be on suboptimal medical treatment. Another 1738 patients from Scotland were included in a validation cohort. Overall, both patient cohorts were well matched. The majority of patients were hospitalized for acute heart failure, and the remainder presented with worsening signs and\/or symptoms of heart failure at outpatient clinics. Approximately half of the patients were in New York Heart Association class III, and 7% vs 34% of patients of the index vs validation cohort had heart failure with preserved ejection fraction. According to study design, all patients used diuretics, but owing to the inclusion criteria of both cohorts, patients were not on optimal, evidence-based medical therapy. In the follow-up phase, uptitration to guideline-recommended doses was encouraged.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>By using a novel systems biology approach, incorporating demographics, biomarkers, genome-wide analysis, and proteomics, a model that predicts response to therapy will be developed, which should be instrumental in developing alternative therapies for patients with suboptimal response to currently recommended therapies and thus further improve care for patients with heart failure.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ejhf.531","type":"journal-article","created":{"date-parts":[[2016,4,30]],"date-time":"2016-04-30T09:03:28Z","timestamp":1462007008000},"page":"716-726","source":"Crossref","is-referenced-by-count":193,"title":["A Systems BIOlogy Study to TAilored Treatment in Chronic Heart Failure: Rationale, Design, and Baseline Characteristics of BIOSTAT-CHF"],"prefix":"10.1093","volume":"18","author":[{"given":"Adriaan A.","family":"Voors","sequence":"first","affiliation":[{"name":"Department of Cardiology, University of Groningen , Hanzeplein 1, 9713, GZ, Groningen ,","place":["the Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan D.","family":"Anker","sequence":"additional","affiliation":[{"name":"Innovative Clinical Trials, Department of Cardiology and Pneumology, University Medical Centre G\u00f6ttingen (UMG) , G\u00f6ttingen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John G.","family":"Cleland","sequence":"additional","affiliation":[{"name":"National Heart & Lung Institute, Royal Brompton and Harefield Hospitals , Imperial College, London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Dickstein","sequence":"additional","affiliation":[{"name":"University of Bergen , Bergen ,","place":["Norway"]},{"name":"University of Stavanger , Stavanger ,","place":["Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerasimos","family":"Filippatos","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Heart Failure Unit, Athens University Hospital Attikon , Athens ,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pim","family":"van der Harst","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University of Groningen , Hanzeplein 1, 9713, GZ, Groningen ,","place":["the Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans L.","family":"Hillege","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University of Groningen , Hanzeplein 1, 9713, GZ, Groningen ,","place":["the Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chim C.","family":"Lang","sequence":"additional","affiliation":[{"name":"School of Medicine Centre for Cardiovascular and Lung Biology, Division of Medical Sciences, University of Dundee, Ninewells Hospital & Medical School , Dundee ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jozine M.","family":"ter Maaten","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University of Groningen , Hanzeplein 1, 9713, GZ, Groningen ,","place":["the Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leong","family":"Ng","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Sciences, University of Leicester, Glenfield Hospital, and NIHR Leicester Cardiovascular Biomedical Research Unit, Glenfield Hospital , Leicester, LE3 9QP ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Ponikowski","sequence":"additional","affiliation":[{"name":"Department of Heart Diseases, Wroclaw Medical University, Poland and Cardiology Department, Military Hospital , Wroclaw ,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nilesh J.","family":"Samani","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Sciences, University of Leicester, Glenfield Hospital, and NIHR Leicester Cardiovascular Biomedical Research Unit, Glenfield Hospital , Leicester, LE3 9QP ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk J.","family":"van Veldhuisen","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University of Groningen , Hanzeplein 1, 9713, GZ, Groningen ,","place":["the Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faiz","family":"Zannad","sequence":"additional","affiliation":[{"name":"Inserm CIC 1433, Universit\u00e9 de Lorrain , CHU de Nancy, Nancy ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aeilko H.","family":"Zwinderman","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Biostatistics and Bioinformatics, Academic Medical Centre , Amsterdam ,","place":["the Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Metra","sequence":"additional","affiliation":[{"name":"Institute of Cardiology, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia \u00a0","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2016,4,29]]},"reference":[{"key":"2026011721145614000_ejhf531-bib-0001","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1136\/hrt.2003.025270","article-title":"Clinical epidemiology of heart failure","volume":"93","author":"Mosterd","year":"2007","journal-title":"Heart"},{"key":"2026011721145614000_ejhf531-bib-0002","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1161\/CIRCHEARTFAILURE.112.000161","article-title":"Multicenter prospective observational study on acute and chronic heart failure: one-year follow-up results of IN-HF (Italian Network on Heart Failure) outcome registry","volume":"6","author":"Tavazzi","year":"2013","journal-title":"Circ Heart Fail"},{"key":"2026011721145614000_ejhf531-bib-0003","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1093\/eurjhf\/hfs105","article-title":"ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC","volume":"14","author":"McMurray","year":"2012","journal-title":"Eur J Heart Fail"},{"key":"2026011721145614000_ejhf531-bib-0004","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1002\/ejhf.289","article-title":"Recommendations on pre-hospital and early hospital management of acute heart failure: a consensus paper from the Heart Failure Association of the European Society of Cardiology, the European Society of Emergency Medicine and the Society of Academic Emergency Medicine","volume":"17","author":"Mebazaa","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"2026011721145614000_ejhf531-bib-0005","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1002\/ejhf.496","article-title":"Use of evidence-based therapy and survival in heart failure in Sweden 2003\u20132012","volume":"18","author":"Thorvaldsen","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"2026011721145614000_ejhf531-bib-0006","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1093\/eurjhf\/hft050","article-title":"EURObservational Research Programme: regional differences and 1-year follow-up results of the Heart Failure Pilot Survey (ESC-HF Pilot)","volume":"15","author":"Maggioni","year":"2013","journal-title":"Eur J Heart Fail"},{"key":"2026011721145614000_ejhf531-bib-0007","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1093\/eurjhf\/hfr093","article-title":"CONSENSUS to EMPHASIS: the overwhelming evidence which makes blockade of the renin-angiotensin-aldosterone system the cornerstone of therapy for systolic heart failure","volume":"13","author":"McMurray","year":"2011","journal-title":"Eur J Heart Fail"},{"key":"2026011721145614000_ejhf531-bib-0008","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1093\/eurheartj\/ehl250","article-title":"The perindopril in elderly people with chronic heart failure (PEP-CHF) study","volume":"27","author":"Cleland","year":"2006","journal-title":"Eur Heart J"},{"key":"2026011721145614000_ejhf531-bib-0009","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1056\/NEJMoa0706201","article-title":"Rosuvastatin in older patients with systolic heart failure","volume":"357","author":"Kjekshus","year":"2007","journal-title":"N Engl J Med"},{"key":"2026011721145614000_ejhf531-bib-0010","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1001\/jama.297.12.1319","article-title":"Orlandi C; Efficacy of VasoPressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial","volume":"297","author":"Konstam","year":"2007","journal-title":"JAMA"},{"key":"2026011721145614000_ejhf531-bib-0011","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1001\/jama.298.17.2009","article-title":"Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials","volume":"298","author":"McMurray","year":"2007","journal-title":"JAMA"},{"key":"2026011721145614000_ejhf531-bib-0012","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1056\/NEJMoa0805450","article-title":"Irbesartan in patients with heart failure and preserved ejection fraction","volume":"359","author":"Massie","year":"2008","journal-title":"N Engl J Med"},{"key":"2026011721145614000_ejhf531-bib-0013","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/S0140-6736(08)61240-4","article-title":"Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial","volume":"372","author":"Tavazzi","year":"2008","journal-title":"Lancet"},{"key":"2026011721145614000_ejhf531-bib-0014","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N Engl J Med"},{"key":"2026011721145614000_ejhf531-bib-0015","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"2026011721145614000_ejhf531-bib-0016","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.ejheart.2008.08.005","article-title":"ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM)","volume":"10","author":"Dickstein","year":"2008","journal-title":"Eur J Heart Fail"},{"key":"2026011721145614000_ejhf531-bib-0017","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1007\/s40138-014-0040-z","article-title":"Vasodilators in acute heart failure: review of the latest studies","volume":"2","author":"Levy","year":"2014","journal-title":"Curr Emerg Hosp Med Rep"},{"key":"2026011721145614000_ejhf531-bib-0018","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1002\/ejhf.294","article-title":"Agents with vasodilator properties in acute heart failure: how to design successful trials","volume":"17","author":"Mebazaa","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"2026011721145614000_ejhf531-bib-0019","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1056\/NEJM200105033441802","article-title":"Lesser response to angiotensin-converting-enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction","volume":"344","author":"Exner","year":"2001","journal-title":"N Engl J Med"},{"key":"2026011721145614000_ejhf531-bib-0020","first-page":"288","article-title":"A novel approach to drug development in heart failure: towards personalized medicine","volume":"30","author":"Liu","year":"2014","journal-title":"Can J Cardiol"},{"key":"2026011721145614000_ejhf531-bib-0021","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s10741-013-9396-5","article-title":"Clinical use of novel biomarkers in heart failure: towards personalized medicine","volume":"19","author":"Schmitter","year":"2014","journal-title":"Heart Fail Rev"},{"key":"2026011721145614000_ejhf531-bib-0022","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1002\/ejhf.273","article-title":"State of the art: newer biomarkers in heart failure","volume":"17","author":"de Boer","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"2026011721145614000_ejhf531-bib-0023","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1002\/ejhf.438","article-title":"Can circulating biomarkers identify heart failure patients at low risk","volume":"17","author":"Richards","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"2026011721145614000_ejhf531-bib-0024","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1002\/ejhf.414","article-title":"Brunner-La Rocca HP; TIME-CHF investigators. Circulating biomarkers of distinct pathophysiological pathways in heart failure with preserved vs. reduced left ventricular ejection fraction","volume":"17","author":"Sanders-van Wijk","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"2026011721145614000_ejhf531-bib-0025","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1136\/heart.83.3.257","article-title":"Is there a role for renin profiling in selecting chronic heart failure patients for ACE inhibitor treatment?","volume":"83","author":"Lim","year":"2000","journal-title":"Heart"},{"key":"2026011721145614000_ejhf531-bib-0026","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1001\/jama.280.13.1168","article-title":"Age\u2013race subgroup compared with renin profile as predictors of blood pressure response to antihypertensive therapy. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents","volume":"280","author":"Preston","year":"1998","journal-title":"JAMA"},{"key":"2026011721145614000_ejhf531-bib-0027","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S0895-7061(99)00030-8","article-title":"The renin\u2013angiotensin system and blood pressure: differences between blacks and whites","volume":"12","author":"He","year":"1999","journal-title":"Am J Hypertens"},{"key":"2026011721145614000_ejhf531-bib-0028","doi-asserted-by":"crossref","first-page":"11288","DOI":"10.1073\/pnas.0509937103","article-title":"A polymorphism within a conserved beta(1)-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure","volume":"103","author":"Liggett","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026011721145614000_ejhf531-bib-0029","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/nature01254","article-title":"Computational systems biology","volume":"420","author":"Kitano","year":"2002","journal-title":"Nature"}],"container-title":["European Journal of Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fejhf.531","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ejhf.531","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ejhf.531","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/18\/6\/716\/66381048\/eurjhf_18_6_716.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/18\/6\/716\/66381048\/eurjhf_18_6_716.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T02:15:27Z","timestamp":1768702527000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjhf\/article\/18\/6\/716\/8423343"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4,29]]},"references-count":29,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2016,4,29]]},"published-print":{"date-parts":[[2016,6,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ejhf.531","relation":{},"ISSN":["1388-9842","1879-0844"],"issn-type":[{"value":"1388-9842","type":"print"},{"value":"1879-0844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2016,6]]},"published":{"date-parts":[[2016,4,29]]}}}